Chronic Myeloid Neoplasias and Clonal Overlap Syndromes [recurso electrónico] : Epidemiology, Pathophysiology and Treatment Options / edited by Richard Greil, Lisa Pleyer, Viktoria Faber, Daniel Neureiter.

Por: Greil, Richard [editor.]Colaborador(es): Pleyer, Lisa [editor.] | Faber, Viktoria [editor.] | Neureiter, Daniel [editor.] | SpringerLink (Online service)Tipo de material: TextoTextoEditor: Vienna : Springer Vienna, 2010Descripción: XI, 295 p. online resourceTipo de contenido: text Tipo de medio: computer Tipo de portador: online resourceISBN: 9783211798928Tema(s): Medicine | Internal medicine | Blood transfusion | Oncology | Medicine & Public Health | Oncology | Internal Medicine | Blood Transfusion MedicineFormatos físicos adicionales: Printed edition:: Sin títuloClasificación CDD: 616.994 Clasificación LoC:RC254-282Recursos en línea: Libro electrónicoTexto
Contenidos:
to “Classic” Chronic Myeloproliferative Disorders (CMPDs) — Molecular and Cellular Biology -- Essential Thrombocythemia (ET) -- Polycythemia Vera (PV) -- Primary Myelofibrosis (PMF) [Previously Chronic Idiopathic Myelofibrosid (CIMF), Myelofibrosis with Myeloid Metaplasia (MMM), Agnogenic Myeloid Metaplasia (AMM)] -- Chronic myelogenous leukemia (CML) -- Myelodysplastic Syndromes (MDS) -- Chronic Myelomonocytic Leukemia (CMML) -- Rare Clonal Myeloid Diseases -- De novo “Classic” Paroxysmal Nocturnal Hemoglobinuria (PNH) (Marchiafava-Micheli Syndrome) -- Clonal Bone Marrow Failure Overlap Syndromes.
En: Springer eBooksResumen: Introduction The understanding of the genetic, epigenetic, immuno- well as for practicing hematologists or oncologists. logical and biological causes of myeloproliferative dis- Each chapter follows a similar architecture and leads orders has substantially improved in the last few years. through epidemiology, genetic and molecular causes, Together with refined tools in pathology, the successful hematological and clinical findings, prognostic factors establishment of mouse models mimicking at least some and current treatment approaches of the diseases. of the myeloproliferative disorders, and murine models Effort has been made to point out the evolving field of novel drugs in this arena but simultaneously diff- allowing to carefully dissect the role of mutations and gene dosage effects of, for example JAK2, this has led to entiate between standard and experimental treatment ever increasing numbers of modified classification approaches. schemes. It is therefore important for the heamtologist Together with the co-editors and all the authors of or oncologist to keep up with this rapid change in classi- the various chapters I hope that the readers of the book fication language, the upcoming of new entities or differ- will enjoy reading and benefit from the information entiation between, or subclassification of, rare diseases provided.
Star ratings
    Valoración media: 0.0 (0 votos)
Existencias
Tipo de ítem Biblioteca actual Colección Signatura Copia número Estado Fecha de vencimiento Código de barras
Libro Electrónico Biblioteca Electrónica
Colección de Libros Electrónicos RC254 -282 (Browse shelf(Abre debajo)) 1 No para préstamo 373076-2001

to “Classic” Chronic Myeloproliferative Disorders (CMPDs) — Molecular and Cellular Biology -- Essential Thrombocythemia (ET) -- Polycythemia Vera (PV) -- Primary Myelofibrosis (PMF) [Previously Chronic Idiopathic Myelofibrosid (CIMF), Myelofibrosis with Myeloid Metaplasia (MMM), Agnogenic Myeloid Metaplasia (AMM)] -- Chronic myelogenous leukemia (CML) -- Myelodysplastic Syndromes (MDS) -- Chronic Myelomonocytic Leukemia (CMML) -- Rare Clonal Myeloid Diseases -- De novo “Classic” Paroxysmal Nocturnal Hemoglobinuria (PNH) (Marchiafava-Micheli Syndrome) -- Clonal Bone Marrow Failure Overlap Syndromes.

Introduction The understanding of the genetic, epigenetic, immuno- well as for practicing hematologists or oncologists. logical and biological causes of myeloproliferative dis- Each chapter follows a similar architecture and leads orders has substantially improved in the last few years. through epidemiology, genetic and molecular causes, Together with refined tools in pathology, the successful hematological and clinical findings, prognostic factors establishment of mouse models mimicking at least some and current treatment approaches of the diseases. of the myeloproliferative disorders, and murine models Effort has been made to point out the evolving field of novel drugs in this arena but simultaneously diff- allowing to carefully dissect the role of mutations and gene dosage effects of, for example JAK2, this has led to entiate between standard and experimental treatment ever increasing numbers of modified classification approaches. schemes. It is therefore important for the heamtologist Together with the co-editors and all the authors of or oncologist to keep up with this rapid change in classi- the various chapters I hope that the readers of the book fication language, the upcoming of new entities or differ- will enjoy reading and benefit from the information entiation between, or subclassification of, rare diseases provided.

19

Con tecnología Koha